Caroline J. Dore

Caroline J. Dore

Auto-generated profile, based on publicly available information

Caroline J. Dore

Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, UCL, London, UK

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2014 in Trials
Verified
Journal Article
Open access
PDF file
BKBrennan C Kahan
Brennan C Kahan
VJVipul Jairath
Vipul Jairath
CDCaroline J Doré
Caroline J Doré
TMTim P Morris
Tim P Morris
Adjustment for prognostic covariates can lead to increased power in the analysis of randomized trials. However, adjusted analyses are not often performed in practice.

1 December 2021 in Annals of Internal Medicine
Verified
Journal Article
Closed access
MSMuhammad Shipa
Muhammad Shipa
AEAndrew Embleton-Thirsk
Andrew Embleton-Thirsk
MPMariea Parvaz
Mariea Parvaz
LSLiliana Ribeiro Santos
Liliana Ribeiro Santos
PMPatrick Muller
Patrick Muller
SHSally Hamour
Sally Hamour
Rituximab is commonly used for patients with systemic lupus erythematosus (SLE) that is refractory to conventional therapy, but it yields variable responses. This phase 2 clinical trial sought to o... Visual Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus. Rituximab is commonly used for patients with systemic lupus erythematosus (SLE) that is refractory to con... Background: B-cell depletion with rituximab is commonly used for patients with systemic lupus erythematosus (SLE) that is refractory to conventional therapy, but it yields variable responses. We hy...

31 August 2020 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
SZStéphane Zuily
Stéphane Zuily
HCHannah Cohen
Hannah Cohen
DIDavid A. Isenberg
David A. Isenberg
SWScott C. Woller
Scott C. Woller
MCMark Crowther
Mark Crowther
KDKatrien MJ Devreese
Katrien MJ Devreese

1 November 2016 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
NAN.K. Arden
N.K. Arden
SCS. Cro
S. Cro
SSS. Sheard
S. Sheard
CDC.J. Doré
C.J. Doré
ABA. Bara
A. Bara
RKR. Keen
R. Keen

21 November 2014 in Trials
Verified
Journal Article
Open access
PDF file
BKBrennan C Kahan
Brennan C Kahan
SCSuzie Cro
Suzie Cro
CDCaroline J Doré
Caroline J Doré
DBDaniel J Bratton
Daniel J Bratton
SRSunita Rehal
Sunita Rehal
VJVipul Jairath
Vipul Jairath
Blinded outcome assessment is recommended in open-label trials to reduce bias, however it is not always feasible. It is therefore important to find other means of reducing bias in these scenarios. We describe two randomised trials where blinded outcome assessment was not possible, and discuss the strategies used to reduce the possibility of bias. TRIGGER was an open-label cluster randomised trial whose primary outcome was further bleeding. Because of the cluster randomisation, all researchers in a hospital were aware of treatment allocation and so could not perform a blinded assessment. A blinded adjudication committee was also not feasible as it was impossible to compile relevant information to send to the committee in a blinded manner. Therefore, the definition of further bleeding was modified to exclude subjective aspects (such as whether symptoms like vomiting blood were severe enough to indicate the outcome had been met), leaving only objective aspects (the presence versus absence of active bleeding in the upper gastrointestinal tract confirmed by an internal examination). TAPPS was an open-label trial whose primary outcome was whether the patient was referred for a pleural drainage procedure. Allowing a blinded assessor to decide whether to refer the patient for a procedure was not feasible as many clinicians may be reluctant to enrol patients into the trial if they cannot be involved in their care during follow-up. Assessment by an adjudication committee was not possible, as the outcome either occurred or did not. Therefore, the decision pathway for procedure referral was modified. If a chest x-ray indicated that more than a third of the pleural space filled with fluid, the patient could be referred for a procedure; otherwise, the unblinded clinician was required to reach a consensus on referral with a blinded assessor. This process allowed the unblinded clinician to be involved in the patient’s care, while reducing the potential for bias. When blinded outcome assessment is not possible, it may be useful to modify the outcome definition or method of assessment to reduce the risk of bias. TRIGGER: ISRCTN85757829 . Registered 26 July 2012. TAPPS: ISRCTN47845793 . Registered 28 May 2012.

1 December 2022 in Annals of Internal Medicine
Verified
Journal Article
Closed access
AGAndrew J. Goldberg
Andrew J. Goldberg
KCKashfia Chowdhury
Kashfia Chowdhury
EBEkaterina Bordea
Ekaterina Bordea
IHIva Hauptmannova
Iva Hauptmannova
JBJames Blackstone
James Blackstone
TGTARVA Study Group†
TARVA Study Group†
Surgical options for end-stage ankle osteoarthritis include total ankle replacement and ankle fusion. This randomized trial compares the benefits on walking and standing clinical scores and adverse... Visual Total Ankle Replacement vs. Arthrodesis for End-Stage Ankle Osteoarthritis. Surgical options for end-stage ankle osteoarthritis include total ankle replacement and ankle fusion. Thi... Background: End-stage ankle osteoarthritis causes severe pain and disability. There are no randomized trials comparing the 2 main surgical treatments: total ankle replacement (TAR) and ankle fusion...